Live
Endpoints NewsAmgen launches late-stage obesity trial in patients who switch from rival drugsFierceBiotech‘M&A used to be the only way to go’: Why Seaport’s CEO opted for route to upsized $255M IPOBioWorldMoney raised by biopharmaBioWorldBiopharma money raised: Jan. 1-April 30, 2026Endpoints NewsQ&A: Seaport CEO and CSO on learning from Karuna and the future of CNS researchBioPharma DiveSummit’s ‘self-inflicted’ stumble; Esperion’s take-private dealBioPharma DiveModerna sees revenue bump from international COVID vaccine salesEndpoints NewsSamsung Biologics workers begin five-day strike over wage disputesFierceBiotechSummit's PD-1xVEGF interim trial miss surprises analysts, shares tumbleEndpoints NewsAcelyrin founder Shao-Lee Lin emerges at Cue, as it becomes latest to license from ChinaEndpoints NewsSave the date: Premium subscriber-exclusive Post-Hoc LiveEndpoints NewsFDA approval for Alzheimer's agitation drug; Esperion goes private in $1.1B deal

Archive

Latest Oldest Clear
@LAUDA China Co., Ltd.
Total 1
Source LAUDA China Co., Ltd.
Query --